The prescribing information for Avandia (rosiglitazone maleate, from GlaxoSmithKline) has been updated to include clinical findings demonstrating sustained glycemic control for up to 5 years in type 2 diabetes. In the ADOPT study, a head-to-head trial comparing Avandia to glyburide and metformin monotherapy, the percentage of patients with inadequate glucose control at 5 years was 34% with glyburide, 21% with metformin, and 15% with Avandia.

Avandia is indicated as an adjunct to diet and exercise in type 2 diabetes, as monotherapy, or in combination with metformin and/or a sulfonylurea.

For more information call (888) 825-5249 or visit www.avandia.com.